Clinical Trial Update: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy [Phase 2]

View source ↗

Summary

Phase II trial evaluating frontline triplet therapy with venetoclax, obinutuzumab, and bendamustine in patients with high tumor burden follicular lymphoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular | Phase 2 | Status: COMPLETED | Results posted: 2022-07-18